26,100 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Varma Mutual Pension Insurance Co

Key Points

• Varma Mutual Pension Insurance Co. bought a new stake of 26,100 shares (~$10.38M) in Alnylam Pharmaceuticals during Q4, while institutional investors collectively own 92.97% of the company.
• Alnylam reported a strong quarter with $1.99 EPS vs. $0.87 expected and revenue of $1.17B (up 96.4% year-over-year), and analysts maintain a "Moderate Buy" consensus with an average price target of $471.96.
• Company insiders have been net sellers recently — 38,656 shares sold (~$12.37M) in the last 90 days — and insiders now own just 0.86% of the stock.

Varma Mutual Pension Insurance Co purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 26,100 shares of the biopharmaceutical company's stock, valued at approximately $10,379,000.

Several other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company's stock valued at $6,185,846,000 after acquiring an additional 268,313 shares in the last quarter. Capital Research Global Investors raised its holdings in Alnylam Pharmaceuticals by 0.4% in the 3rd quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company's stock valued at $3,293,516,000 after acquiring an additional 31,184 shares in the last quarter. Groupama Asset Managment raised its holdings in Alnylam Pharmaceuticals by 160.4% in the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company's stock valued at $18,610,000 after acquiring an additional 2,483,697 shares in the last quarter. Orbis Allan Gray Ltd raised its holdings in Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock valued at $691,771,000 after acquiring an additional 486,489 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Alnylam Pharmaceuticals by 698.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company's stock valued at $618,158,000 after acquiring an additional 1,185,909 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several recent research reports. Needham & Company LLC cut their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a "buy" rating for the company in a report on Thursday, February 12th. Truist Financial cut their price target on Alnylam Pharmaceuticals from $515.00 to $505.00 and set a "buy" rating for the company in a report on Monday, April 13th. Barclays started coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They issued an "overweight" rating and a $527.00 price target for the company. Chardan Capital reiterated a "buy" rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Finally, Oppenheimer started coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They issued an "outperform" rating and a $500.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $471.96.

Alnylam Pharmaceuticals Trading Up 1.1%

ALNY stock opened at $301.11 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $245.96 and a 1-year high of $495.55. The firm has a market cap of $40.20 billion, a P/E ratio of 82.27 and a beta of 0.31. The business's 50 day moving average is $319.41 and its 200-day moving average is $374.99. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period in the prior year, the company posted ($0.44) EPS. The company's revenue was up 96.4% compared to the same quarter last year. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.78 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Melissa Mclaughlin sold 2,286 shares of the business's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the transaction, the insider directly owned 9,443 shares of the company's stock, valued at $3,120,156.06. The trade was a 19.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the business's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $722,795.90. Following the completion of the transaction, the executive vice president directly owned 64,273 shares in the company, valued at $21,059,048.45. The trade was a 3.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 38,656 shares of company stock worth $12,370,696. Insiders own 0.86% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.